Curated News
By: NewsRamp Editorial Staff
July 16, 2024

MediVera Compounding Pharmacy™ Announces Rebranding and Strong Revenue Growth

TLDR

  • The rebranding of University Compounding Pharmacy as MediVera Compounding Pharmacy™ provides a strong advantage through nationwide expansion and new product offerings.
  • MediVera Compounding Pharmacy™ has been dedicated to providing personalized medicine since 1999 and is licensed in and ships to 33 states.
  • The company's commitment to tailored solutions for healthcare providers and patients is making the world a better place by setting industry standards and offering exceptional care.
  • MediVera Compounding Pharmacy™ is poised for strong growth in 2024 with expansion plans into 14 additional states and the Impressed Advantage program making the prescription process easier and faster.

Impact - Why it Matters

This news matters as it signifies the evolution of a leading pharmacy, offering enhanced services and products to healthcare providers and patients. The rebranding and revenue growth demonstrate the company's commitment to quality and innovation, ultimately benefiting those who rely on personalized medicine.

Summary

University Compounding Pharmacy, a leader in personalized medicine since 1999, is rebranding as MediVera Compounding Pharmacy™. The company's growth, new product offerings, nationwide expansion, and differentiated quality products and services have led to a substantial increase in revenue. The rebranding is accompanied by the launch of the Impressed Advantage customer service program, making the prescription process easier and faster for healthcare providers and patients. The company anticipates doubling its revenue once again in 2024 as it expands into 14 additional states.

Source Statement

This curated news summary relied on this press release disributed by News Direct. Read the source press release here, MediVera Compounding Pharmacy™ Announces Rebranding and Strong Revenue Growth

blockchain registration record for the source press release.